News

There has been a significant uptake in mergers and acquisitions activity in the pharmaceutical and life sciences industry in recent years, as a range of factors prompt companies to invest and consolidate. This is significantly important to Ireland, given the number of indigenous and multinational companies that operate in the sector here, and it...

Biogen ($BIIB) is laying off 11% of its workforce and pulling the plug on a handful of pipeline projects, cutting deep into its infrastructure amid mounting pressure and turning its attention to some high-risk R&D programs. Biogen CEO George Scangos The plan is to do away with about 830 jobs by the end of 2015, Biogen said, an effort designed to...

Science Foundation Ireland Public Engagement Initiative aims to Engage and Communicate the Wonders and Opportunities that Science and Innovation Present for Everyone Monthly Focus on Specific Theme Supports Deeper Dive into areas of Scientific Interest 07th April 2016 – Science Foundation Ireland through #ScienceRising is highlighting areas of s...

Join The RFT Group on Social Media to keep up to date with all the latest developments in the Pharmaceutical and Medical Device Industries, we also post our latest available jobs so to ensure you are constantly in the loop get following The RFT Group now on Social Media. LinkedIn: http://bit.ly/1Rqk0aC Facebook: http://bit.ly/1RI0qWc Twitter: @R...

Jazz Pharmaceuticals (NASDAQ: JAZZ) has announced that the US Food and Drug Administration (FDA) has granted marketing approval for Defitelio (defibrotide sodium) for the treatment of adult and paediatric patients with hepatic veno-occlusive disease. Also called sinusoidal obstruction syndrome (SOS), Defitelio is indicated for the treatment of t...

Science Foundation Ireland is seeking to fund researchers who are at the initial stages of developing a new or innovative technology, product, process or service with strong commercial potential. For researchers who wish to pursue the commercialisation of a technology, TIDA provides: Technical validation by independent international peer review ...

Praluent is a proproetin convertase subtilisin/kexin type 9 (or PCSK9) inhibitor that is being evaluated as a treatment in patients with an inherited form of high cholesterol known as heterozygous familial hypercholesterolemia (HeFH). With HeFH, cholesterol levels require chronic, weekly or bi-weekly apheresis therapy, which is a therapy where b...

Sanders asks Treasury to 'block' Pfizer and Allergan merger By Eric Palmer Sen. Bernie Sanders In between campaign stops, presidential candidate Sen. Bernie Sanders is finding time to keep pressure on the pharmaceutical industry. This time he is pushing the U.S. Treasury Department to try to stop Pfizer's ($PFE) $160 billion tax-avoiding merger ...

Doctors taking a shine to biosimilars as they get experience with them March 18, 2016 | By Eric Palmer Three years ago, doctors in Europe displayed grave doubts about using biosimilars instead of branded biologics on their patients. But after a couple of years of experience with a biosimilar of Merck's ($MRK) Remicade (infliximab) from Hospira a...